Systemic sclerosis & Raynaud's
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort
Authors' conclusion
Significant differences are delineated between both a fibrotic and an inflammatory phenotype.
Study context
- Population
- Patients with SSc who underwent a muscle biopsy for suspected myopathy, November 2002 to September 202012 biopsies neurogenic or normal/minimal
- Participants
- 52 patients
- Exposure
- Fibrosing vs inflammatory histological pattern in SSc-associated myopathy
- Outcome
- Clinico-serological features and outcomes, fibrosing vs inflammatory
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- Fibrosing vs Inflammatory
- Ischaemic heart disease prevalence 38.5% vs 3.8%; P = 0.011
- Fibrosing vs Inflammatory
- Conduction abnormalities or arrhythmias 61.5% vs 26.9%; P = 0.036
- Fibrosing vs Inflammatory
- Anti-topo I antibodies 42.9% vs 11.5%; P = 0.044
- Fibrosing vs Inflammatory
- Median ESR 53.5 vs 32.5 mm/h; P = 0.013
- Fibrosing vs Inflammatory
- Mortality 42.9% vs 3.8%; P = 0.004
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort. Rheumatology (Oxford). Published 17 June 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →